

Particulars	FY17	FY18	YoY Growth
	(Rs Crs)		{%}
<b>Total Revenue from Operations (Net of Excise)</b>	<b>5,861</b>	<b>7,518</b>	<b>28%</b>
Pharmaceuticals	3,104	4,013	29%
Life Science Ingredients	2,576	3,328	29%
Drug Discovery Solutions	182	176	-3%
<b>Total Expenditure</b>	<b>4,516</b>	<b>5,999</b>	<b>33%</b>
Other Income	25	40	61%
<b>EBITDA from Operations</b>			
Pharmaceuticals	975	1,006	3%
Life Science Ingredients	434	632	46%
Drug Discovery Solutions	26	19	-28%
Corporate (Expenses)/Income	(65)	(69)	
<b>Total</b>	<b>1,370</b>	<b>1,588</b>	<b>16%</b>
One time expenses - Acquisition related	0	(30)	
<b>Reported EBITDA</b>	<b>1,370</b>	<b>1,558</b>	<b>14%</b>
Depreciation and Amortization	291	415	
Normal	291	324	11%
One-time	0	91	
Finance Cost	341	284	-17%
<b>Profit before Tax</b>	<b>738</b>	<b>859</b>	<b>16%</b>
Tax Expenses (Net)	163	225	38%
Minority Interest	(i)	(8)	
<b>Net Profit After Tax and Minority Interest</b>	<b>576</b>	<b>643</b>	<b>12%</b>
<b>Normalised Profit after Tax</b>	<b>576</b>	<b>744</b>	<b>29%</b>
<b>Earnings Per Share - Face Value Re. 1 (Rs.)</b>	<b>36.93</b>	<b>41.25</b>	
<b>Normalised Earnings Per Share</b>	<b>36.93</b>	<b>47.77</b>	
	(%)		<b>(bps)</b>
EBITDA Margins from Operations	23.4%	21.1%	(225)
Pharmaceuticals	31.4%	25.1%	(635)
Life Science Ingredients	16.8%	19.0%	215
Drug Discovery Solutions	14.2%	10.5%	(371)
Net Margins	9.8%	8.6%	(127)